So about 3 years after the initial report of the results from the CHAARTED trial, 2 years after the initial report from the ADT + docetaxel arm of the STAMPEDE trial, and 3 months after the reports and publication of data from the LATITUDE trial and the ADT + abiraterone arm of the STAMPEDE trial, … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: hormone-resistant, hormone-sensistive, latitude, mCRPC, metastatic, mHSPC, STAMPEDE, Treatment | Leave a comment »
THE "NEW" PROSTATE CANCER INFOLINK 